The management of low-grade glioma (LGG) is still challenging because malignant transformation to a high-grade tumor and/or recurrence after primary therapy may result in an unfavorable outcome. Since CT and MRI have limited capability to detect subtle changes indicative of recurrence, metabolic imaging markers were tested. In earlier studies, increased choline signal in proton magnetic resonance spectroscopy (MRS) was reported in patients with low-to high-grade malignant transformation and posttreatment recurrence in LGG [1] . Positron emission tomography (PET) with 18 F-fluorodeoxyglucose (FDG) was also utilized to detect malignant transformation/ posttreatment recurrence [2] . However, these are not widely utilized in the present clinical setting.
The study by Gómez-Río and colleagues demonstrated that 18 F-fluorocholine PET/CT is useful to detect a recurrence of posttreatment LGG [3] . The value of this study is that the study was prospectively done in comparison with standard/ advanced radiological examinations performed with clinically available procedures at present. In their study, 44 patients treated for LGG undergoing standardized follow-up at a single center were enrolled. They were subdivided into two groups. One was followed by a standard diagnostic approach including advanced MRI (diffusion, perfusion MRI, and proton MRS) and 201 Tl single photon emission computed tomography (SPECT). Another was followed by advanced MRI and 
